NK cells and CD38: Implication for (Immuno)Therapy in Plasma Cell Dyscrasias
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
NK cells and CD38: Implication for (Immuno)Therapy in Plasma Cell Dyscrasias
Authors
Keywords
-
Journal
Cells
Volume 9, Issue 3, Pages 768
Publisher
MDPI AG
Online
2020-03-25
DOI
10.3390/cells9030768
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma
- (2019) Thomas Martin et al. Blood Cancer Journal
- The Mechanism Of Action Of The Anti-CD38 Monoclonal Antibody Isatuximab In Multiple Myelmoa
- (2019) Laura Moreno et al. CLINICAL CANCER RESEARCH
- A Phase Ib study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma
- (2019) Joseph Mikhael et al. BLOOD
- Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
- (2019) Noopur Raje et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
- (2019) Thierry Facon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better?
- (2019) Mattia D’Agostino et al. LEUKEMIA
- Daratumumab augments alloreactive natural killer cell cytotoxicity towards CD38+ multiple myeloma cell lines in a biochemical context mimicking tumour microenvironment conditions
- (2018) Niken M. Mahaweni et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome byEx Vivo–Expanded Autologous NK Cells
- (2018) Yufeng Wang et al. CLINICAL CANCER RESEARCH
- Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
- (2018) María-Victoria Mateos et al. NEW ENGLAND JOURNAL OF MEDICINE
- One-Year Follow-Up of Natural Killer Cell Activity in Multiple Myeloma Patients Treated With Adjuvant Lenalidomide Therapy
- (2018) Laurie Besson et al. Frontiers in Immunology
- Natural Killer Cells: Development, Maturation, and Clinical Utilization
- (2018) Alex M. Abel et al. Frontiers in Immunology
- Restoring Natural Killer Cell Immunity against Multiple Myeloma in the Era of New Drugs
- (2017) Gianfranco Pittari et al. Frontiers in Immunology
- The Molecular Mechanism of Natural Killer Cells Function and Its Importance in Cancer Immunotherapy
- (2017) Sourav Paul et al. Frontiers in Immunology
- Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
- (2016) J. Krejcik et al. BLOOD
- Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
- (2016) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis
- (2015) Bruno Paiva et al. BLOOD
- How Do Cytotoxic Lymphocytes Kill Cancer Cells?
- (2015) L. Martinez-Lostao et al. CLINICAL CANCER RESEARCH
- A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma
- (2015) D. M. Benson et al. CLINICAL CANCER RESEARCH
- CD56brightCD16−NK Cells Produce Adenosine through a CD38-Mediated Pathway and Act as Regulatory Cells Inhibiting Autologous CD4+T Cell Proliferation
- (2015) Fabio Morandi et al. JOURNAL OF IMMUNOLOGY
- Human Cytokine-Induced Memory-Like Natural Killer Cells
- (2015) Melissa M. Berrien-Elliott et al. Journal of Innate Immunity
- Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
- (2015) Sagar Lonial et al. NEW ENGLAND JOURNAL OF MEDICINE
- Erratum: The cellular immune system in myelomagenesis: NK cells and T cells in the development of MM and their uses in immunotherapies
- (2015) T Dosani et al. Blood Cancer Journal
- NKG2D Receptor and Its Ligands in Host Defense
- (2015) L. L. Lanier Cancer Immunology Research
- Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways
- (2014) Balaji Balasa et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma
- (2014) N. Korde et al. HAEMATOLOGICA
- Comparison of primary human cytotoxic T-cell and natural killer cell responses reveal similar molecular requirements for lytic granule exocytosis but differences in cytokine production
- (2013) S. C. C. Chiang et al. BLOOD
- Natural killer cell biology: An update and future directions
- (2013) Kerry S. Campbell et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Elotuzumab in Combination With Lenalidomide and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma
- (2012) Sagar Lonial et al. JOURNAL OF CLINICAL ONCOLOGY
- Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors
- (2010) M. de Weers et al. JOURNAL OF IMMUNOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started